Traws Pharma agrees to sell up to $50 million in common stock to Roth Principal Investments
Traws Pharma entered a Common Stock Purchase Agreement with Roth Principal Investments, allowing the company to sell up to $50,000,000 of newly issued common stock over time at its own discretion. The company is under no obligation to sell any shares, and sales can begin only after a registration statement covering the resale of those shares is declared effective by the SEC.
Key points
- Total commitment of up to $50,000,000 in newly issued common stock, at the company's option
- Purchase price set at 94.0% of volume weighted average price, a fixed 6.0% discount, for market open, intraday, pre-market and post-market purchases
- Sales require the closing price to be at least $0.10 (Threshold Price) and an effective registration statement; the period runs 36 months from the Commencement Date
- Agreement dated October 23, 2026, with a related Registration Rights Agreement
The filing
Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 23, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.